AZALEA-TIMI 71

AZALEA-TIMI 71 is a phase 2b, multicenter, randomized, active-controlled study to evaluate the safety and tolerability of two blinded doses of the novel factor XI inhibitor abelacimab compared with open-label rivaroxaban in patients with atrial fibrillation.

AZALEA - TIMI 71 Design Slide

AZALEA on ClinicalTrials.gov

CONTACT US about AZALEA

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close